» Articles » PMID: 30225535

Contact Dermatitis in Atopic Dermatitis Children-Past, Present, and Future

Overview
Date 2018 Sep 19
PMID 30225535
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Allergic contact dermatitis (ACD) used to be considered a rarity in children, but recently has been estimated to effect 4.4 million children in the USA alone, with a notable rise in investigative research in the field of pediatric ACD. Researchers have shown that patch testing is safe and effective in afflicted children and that those with atopic dermatitis (AD) have similar sensitization rates, although they have a higher sensitization to certain allergens, thought to be related to the inflammatory (IL-4) milieu. Patch testing assessment guidelines in children include five key considerations: if a patient's dermatitis worsens, changes distribution, fails to improve with topical therapy, or immediately rebounds after removal of topical treatments; if a patient has a particular distribution of dermatitis; if a working patient has hand eczema that fails to improve with therapy; if the patient has AD that started in adolescence or adulthood with definitely no history of childhood eczema; and importantly, if a patient has severe or widespread atopic dermatitis that will require immunosuppressive systemic medication.

Citing Articles

An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis.

Saeki H, Ohya Y, Baba N, Imamura T, Yokota D, Tsubouchi H Dermatol Ther (Heidelb). 2024; 14(9):2443-2455.

PMID: 39075274 PMC: 11393375. DOI: 10.1007/s13555-024-01236-7.


Photodermatoses in patients with atopic dermatitis: A 10-year retrospective cohort study.

Afvari S, Zippin J J Am Acad Dermatol. 2024; 90(5):1071-1074.

PMID: 38372681 PMC: 11823502. DOI: 10.1016/j.jaad.2024.01.032.


Antioxidant Activity of Quercetin-Containing Liposomes-in-Gel and Its Effect on Prevention and Treatment of Cutaneous Eczema.

Liu C, Cheng X, Wu Y, Xu W, Xia H, Jia R Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631099 PMC: 10458784. DOI: 10.3390/ph16081184.


Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches.

Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N, Stingeni L Front Med (Lausanne). 2023; 10:1184289.

PMID: 37283623 PMC: 10239928. DOI: 10.3389/fmed.2023.1184289.


Similar Skin Barrier Function in Persons with Type 1 Diabetes Compared with Healthy Controls.

Berg A, Grauslund A, Norgaard K, Thorsen S, Zachariae C, Halling A JID Innov. 2023; 3(4):100200.

PMID: 37205305 PMC: 10186598. DOI: 10.1016/j.xjidi.2023.100200.


References
1.
Roul S, Ducombs G, Taieb A . Usefulness of the European standard series for patch testing in children. A 3-year single-centre study of 337 patients. Contact Dermatitis. 1999; 40(5):232-5. DOI: 10.1111/j.1600-0536.1999.tb06054.x. View

2.
Dieli F, Sireci G, Scire E, Salerno A, Bellavia A . Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin-4-deficient mice. Immunology. 1999; 98(1):71-9. PMC: 2326896. DOI: 10.1046/j.1365-2567.1999.00844.x. View

3.
Bruckner A, Weston W, Morelli J . Does sensitization to contact allergens begin in infancy?. Pediatrics. 2000; 105(1):e3. DOI: 10.1542/peds.105.1.e3. View

4.
Yosipovitch G, Maayan-Metzger A, Merlob P, Sirota L . Skin barrier properties in different body areas in neonates. Pediatrics. 2000; 106(1 Pt 1):105-8. DOI: 10.1542/peds.106.1.105. View

5.
Mowad C . Methylchloro-isothiazolinone revisited. Am J Contact Dermat. 2000; 11(2):115-8. DOI: 10.1053/ac.2000.6344. View